Cargando…

PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer

BACKGROUND: Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring PD-L1 expression could help to select NSCLC candidates for immunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) PET/CT could...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaodong, Huang, Yan, Zhao, Qingping, Wang, Lei, Song, Xiao, Li, Yi, Jiang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237589/
https://www.ncbi.nlm.nih.gov/pubmed/32430866
http://dx.doi.org/10.1186/s13550-020-00639-9
_version_ 1783536346661388288
author Wu, Xiaodong
Huang, Yan
Zhao, Qingping
Wang, Lei
Song, Xiao
Li, Yi
Jiang, Lei
author_facet Wu, Xiaodong
Huang, Yan
Zhao, Qingping
Wang, Lei
Song, Xiao
Li, Yi
Jiang, Lei
author_sort Wu, Xiaodong
collection PubMed
description BACKGROUND: Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring PD-L1 expression could help to select NSCLC candidates for immunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) PET/CT could provide phenotypic information on malignant tumors. Thus, this study investigated PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in NSCLC. METHODS: FDG PET/CT metabolic parameters including maximum standard uptake (SUVmax), metabolic tumor volume and total lesion glycolysis of primary lesion (MTV-P, TLG-P), and combination of primary lesion and metastases (MTV-C, TLG-C) were compared with PD-L1-positive expression in patients with NSCLC. Moreover, clinicopathological characteristics, including age, gender, smoking history, serum tumor markers, tumor location, size, TNM stage, and genetic mutation were also reviewed. RESULTS: All 374 patients (215 men; 159 women; age 63 ± 9 years) included 283 adenocarcinomas (ACs) and 91 squamous cell carcinomas (SCCs). PD-L1 expression was positive in 27.8% (104/374) cases. SUVmax, TLG-P, and TLG-C of PD-L1 positivity were significantly higher than PD-L1 negativity. Moreover, PD-L1 expression was obviously correlated with man, smoking, and central NSCLC. If ACs and SCCs were separately analyzed, PD-L1 positivity in ACs and SCCs was 21.6% (61/283) and 47.5% (43/91), respectively, and only SUVmax was obviously associated with PD-L1 expression. Furthermore, multivariate analysis revealed that only SUVmax was an independent predictor of PD-L1 positive expression in overall NSCLC, AC, and SCC. Using a SUVmax cut-off value of 12.5, PD-L1 status of NSCLC was predicted by FDG PET/CT with sensitivity, specificity, and accuracy of 65.4%, 86.7%, and 80.7%, respectively. CONCLUSIONS: PD-L1 expression of NSCLC was related to SUVmax, TLG, man, smoking, and central location. However, only SUVmax was an independent predictor of PD-L1 positivity, which could help to explore the existence of immune checkpoints.
format Online
Article
Text
id pubmed-7237589
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72375892020-05-27 PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer Wu, Xiaodong Huang, Yan Zhao, Qingping Wang, Lei Song, Xiao Li, Yi Jiang, Lei EJNMMI Res Original Research BACKGROUND: Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring PD-L1 expression could help to select NSCLC candidates for immunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) PET/CT could provide phenotypic information on malignant tumors. Thus, this study investigated PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in NSCLC. METHODS: FDG PET/CT metabolic parameters including maximum standard uptake (SUVmax), metabolic tumor volume and total lesion glycolysis of primary lesion (MTV-P, TLG-P), and combination of primary lesion and metastases (MTV-C, TLG-C) were compared with PD-L1-positive expression in patients with NSCLC. Moreover, clinicopathological characteristics, including age, gender, smoking history, serum tumor markers, tumor location, size, TNM stage, and genetic mutation were also reviewed. RESULTS: All 374 patients (215 men; 159 women; age 63 ± 9 years) included 283 adenocarcinomas (ACs) and 91 squamous cell carcinomas (SCCs). PD-L1 expression was positive in 27.8% (104/374) cases. SUVmax, TLG-P, and TLG-C of PD-L1 positivity were significantly higher than PD-L1 negativity. Moreover, PD-L1 expression was obviously correlated with man, smoking, and central NSCLC. If ACs and SCCs were separately analyzed, PD-L1 positivity in ACs and SCCs was 21.6% (61/283) and 47.5% (43/91), respectively, and only SUVmax was obviously associated with PD-L1 expression. Furthermore, multivariate analysis revealed that only SUVmax was an independent predictor of PD-L1 positive expression in overall NSCLC, AC, and SCC. Using a SUVmax cut-off value of 12.5, PD-L1 status of NSCLC was predicted by FDG PET/CT with sensitivity, specificity, and accuracy of 65.4%, 86.7%, and 80.7%, respectively. CONCLUSIONS: PD-L1 expression of NSCLC was related to SUVmax, TLG, man, smoking, and central location. However, only SUVmax was an independent predictor of PD-L1 positivity, which could help to explore the existence of immune checkpoints. Springer Berlin Heidelberg 2020-05-19 /pmc/articles/PMC7237589/ /pubmed/32430866 http://dx.doi.org/10.1186/s13550-020-00639-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Wu, Xiaodong
Huang, Yan
Zhao, Qingping
Wang, Lei
Song, Xiao
Li, Yi
Jiang, Lei
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
title PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
title_full PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
title_fullStr PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
title_full_unstemmed PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
title_short PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
title_sort pd-l1 expression correlation with metabolic parameters of fdg pet/ct and clinicopathological characteristics in non-small cell lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237589/
https://www.ncbi.nlm.nih.gov/pubmed/32430866
http://dx.doi.org/10.1186/s13550-020-00639-9
work_keys_str_mv AT wuxiaodong pdl1expressioncorrelationwithmetabolicparametersoffdgpetctandclinicopathologicalcharacteristicsinnonsmallcelllungcancer
AT huangyan pdl1expressioncorrelationwithmetabolicparametersoffdgpetctandclinicopathologicalcharacteristicsinnonsmallcelllungcancer
AT zhaoqingping pdl1expressioncorrelationwithmetabolicparametersoffdgpetctandclinicopathologicalcharacteristicsinnonsmallcelllungcancer
AT wanglei pdl1expressioncorrelationwithmetabolicparametersoffdgpetctandclinicopathologicalcharacteristicsinnonsmallcelllungcancer
AT songxiao pdl1expressioncorrelationwithmetabolicparametersoffdgpetctandclinicopathologicalcharacteristicsinnonsmallcelllungcancer
AT liyi pdl1expressioncorrelationwithmetabolicparametersoffdgpetctandclinicopathologicalcharacteristicsinnonsmallcelllungcancer
AT jianglei pdl1expressioncorrelationwithmetabolicparametersoffdgpetctandclinicopathologicalcharacteristicsinnonsmallcelllungcancer